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Abstract
Background: Although there is a general agreement on the benefits of evidence informed health policy 
development given resource constraints especially in Low-Income Countries (LICs), the definition of what evidence 
is, and what evidence is suitable to guide decision-making is still unclear. Our study is contributing to filling this 
knowledge gap. We aimed to explore health policy actors’ views regarding what evidence they deemed appropriate 
to guide health policy development.
Methods: Using exploratory qualitative methods, we conducted interviews with 51 key informants using an in-
depth interview guide. We interviewed a diverse group of stakeholders in health policy development and knowledge 
translation in the Uganda health sector. Data were analyzed using inductive content analysis techniques. 
Results: Different stakeholders lay emphasis on different kinds of evidence. While donors preferred international 
evidence and Ministry of  Health (MoH) officials looked to local evidence, district health managers preferred local 
evidence, evidence from routine monitoring and evaluation, and reports from service providers. Service providers 
on the other hand preferred local evidence and routine monitoring and evaluation reports whilst researchers 
preferred systematic reviews and clinical trials. Stakeholders preferred evidence covering several aspects impacting 
on decision-making highlighting the fact that although policy actors look for factual information, they also require 
evidence on context and implementation feasibility of a policy decision. 
Conclusion: What LICs like Uganda categorize as evidence suitable for informing policy encompasses several types 
with no consensus on what is deemed as most appropriate. Evidence must be of high quality, applicable, acceptable 
to the users, and informing different aspects of decision-making.
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Implications for policy makers
• Policy development requires different types of evidence and there is no single type of evidence agreed upon as the most appropriate. 
• Different stakeholders attach more importance to different types of evidence. 
• Policies whose implementations impact on several institutions and systems are likely to require more evidence, compared to those where 
implementation only requires minimal adjustments in the current practice.
• The quality of evidence is a very important aspect which creates more confidence in the results, and increases the likelihood of knowledge 
translation.
• In order to ensure that policy-makers receive evidence that meets their expectations, information on their needs is necessary. This could be in 
the form of national research agendas and/or, needs assessment findings. Such an initiative would need to be routine and the needs should be 
updated regularly involving a dialogue between research producers, and policy-makers as research users. 
Implications for public
Multiple forms of evidence inform policy development and are indeed deemed appropriate by policy actors. In this regard, the community also has 
information that can guide policy development in the form of community complaints, for example. Structures and mechanisms need to be put in 
place to enable community participation in forums where different types of evidence are discussed in order to come up with the best policy options.
Key Messages 
Background
The need for evidence-informed health policy development is 
gaining momentum given the growing demand on healthcare 
resources especially in Low-Income Countries (LICs). 
Furthermore, there is need for accountability in governance 
and use of resources with the bench mark being increasing 
equity and coverage of essential interventions, using proven 
strategies in health service delivery. The uptake of evidence 
in policy development generally comes in three different 
ways: it may be used to legitimize or sustain a course of 
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action that policy or decision-makers have already chosen 
to take (symbolic use); may be used to inform debates and 
modify the way decision-makers think and see a given issue 
(conceptual use); or may be directly applied in practice or 
policy (instrumental use) (1). 
The definition of what this evidence is, is still a topic of debate 
with policy-makers, researchers and other stakeholders 
agreeing very little on what constitutes it (2). In this article, 
we adopt the definition of evidence as provided by Lomas et 
al. (3) defining evidence as facts (actual or asserted) intended 
to help the reader reach a conclusion and form an opinion 
about something. We acknowledge that evidence and the 
process of translating it into a decision or some form of 
action is shaped and is influenced by a number of factors 
which have been explored extensively by several scholars 
(4–7). For example, the Overseas Development Institute’s 
Research and Policy in Development (RAPID) framework in 
particular looks at these influences with a LIC perspective. 
It acknowledges that literature on the research-policy link 
is increasingly moving away from older assumptions that 
looked at research to policy as a linear process involving 
two distinct communities of researchers and policy-makers 
dealing with a specific set of findings deemed as ‘knowledge’ 
(7). Instead this linkage is now viewed as a dynamic and 
complex process that is shaped by stakeholder interactions, 
the political context, the evidence available, and several 
external factors. Given these influences, what is deemed 
as evidence may indeed differ in time, place and in a given 
situation.
Although there is a general agreement on the need for, and 
benefits of using evidence to inform policy development 
and practice, and there are multiple forms of evidence to 
provide guidance, what, and how much of this guidance 
counts as evidence, is still not very clear (8,9). The discussion 
regarding suitable evidence to guide policy development is 
a long standing one with researchers generally arguing in 
favor of clinical trials and systematic reviews (9,10). Pang 
however differs from this argument stating that in the case 
of developing countries, evidence needs to be broader than 
that based solely on randomized controlled trials (11). 
Furthermore, Ritter’s findings on how policy-makers access 
evidence when faced with a decision-making opportunity 
(12) show that in fact Pang’s argument may not apply to 
developing countries alone highlighting the fact that, while 
policy-makers are reading and reviewing research, they are 
at the same time looking at other aspects to decision-making 
like political viability and the degree of community support.
Categorizing the quality of evidence is another aspect where 
researchers and policy-makers hold different views. While 
the former attach a lot of importance to methodological rigor 
(2,13), the latter look for important information based on 
quick reflections of the realities of policy and decision-making 
in political and social contexts (2). A systematic review by 
Invaeer et al. (14) found that one of the facilitating factors for 
Knowledge Translation (KT) was whether the available was 
deemed to be of good quality. Noteworthy is the fact that a 
number of frameworks to standardize the definition of what 
good quality is – which is very subjective - have been developed; 
for example, the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) approach (15). The 
challenge is the ability to apply these frameworks given the 
fact that policy-makers, who are usually not equipped with 
skills to use these frameworks, will determine the quality of 
the evidence that they have available. Other characteristics of 
the evidence that have been shown to favor KT include the 
timeliness and relevance of the evidence, and the credibility 
of researchers (16).
Furthermore, the question regarding what evidence is enough 
continues to be debated. There have been suggestions that the 
kinds of evidence relevant for the different stages of the policy 
process do in fact differ (17,18). Therefore, what accounts as 
evidence does in fact vary through the policy cycle.
The views of policy-makers on what evidence is, and what 
evidence is deemed appropriate to inform health policy 
development in a LIC like Uganda, have not been explored 
extensively. Much of the work on the use of evidence in policy 
and decision-making is based on studies of perceptions, of 
which half are perceptions of researchers (14). By the time of 
our research, we did not know of any study that had explored 
policy-makers’ attitudes of what evidence is and which types 
are important for decision-making and in which hierarchy, 
if any, in Uganda. Although lessons can be learned from 
elsewhere, decision-making and KT in particular, is context 
specific. Our study is contributing to filling this knowledge gap 
in the decision-making process in Uganda as a case of a LIC. 
The process of policy development in the Uganda health sector
Policy development is undertaken within a partnership 
between the government and other stakeholders through 
several stages, and within different structures. The process 
of policy development begins with technical discussions 
in technical working groups comprised of government 
officials [the Ministry of Health (MoH) – central and sub-
national level, service providers and relevant line ministries], 
and representatives of donors, researchers, Civil Society 
Organizations (CSOs), the private not-for-profit (PNFP) and 
the private for-profit sector (PFP). Technical working groups 
propose options which are discussed further in the Health 
Policy Advisory Committee (HPAC) and a final decision 
taken regarding the policy option to be adopted. HPAC 
includes representation from the MoH (central and sub-
national (districts) level, service providers), other relevant 
line ministries, donor agencies, the PNFP, PFP and CSO. 
Participation of the sub-national level, CSOs, PNFPs and 
PFP is through representation. Representatives are selected 
through a consultative process within the constituents 
and they collect views from constituency members prior 
to participation in meeting, as well as providing feedback 
regarding decisions taken.
Methods
Getting evidence into policy is a complex process which 
occurs amidst multiple stakeholder interactions embedded 
in a given context and as such, we employed mixed methods 
to capture complexity, enhance comprehensives and validity 
of our results (19). Exploratory qualitative methods which 
are well-suited to capture complexity (19) were employed to 
explore views of respondents, on what evidence they deemed 
appropriate to inform policy development. Quantitative 
methods were employed to assess the frequency with 
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which different types and characteristics of evidence were 
mentioned by the respondents. We conducted interviews with 
key informants using an in-depth interview guide. The study 
was conducted between June, 2012 and August, 2013.
Selection of respondents
Respondents were selected from the national and sub-
national (district) levels. We developed a sampling frame 
based on work done earlier that identified stakeholders 
in health policy development and KT in Uganda (20). At 
the national level, identified stakeholders included the 
MoH, Ministry of Finance (MoF), donor representatives, 
media, CSOs, PNFP and PFP service providers, researchers 
and parliamentarians. Within the identified institutions, 
respondents were purposively selected based on the level 
of seniority in their institutions whereby the most senior 
officers were selected as these were more involved in health 
policy development and evidence generation and; having 
knowledge about the research question (21). Researchers 
were selected on the basis of their previous work on KT and 
focus on health system development, while the journalist 
was selected based on focused reporting on health issues. In 
the case of CSOs, PNFP and PFP, participation in the policy 
process is by representations and the representatives of the 
umbrella organisations were selected. The parliamentarian 
was a member of the social service committee which deals 
with health issues.
At the sub-national level, two districts were selected 
based on proximity to the capital city for easy access given 
resource constraints and, presence of a regional referral 
hospital (Jinja district) or general hospital (Mpigi) to 
obtain perceptions from across the spectrum of healthcare 
delivery system. At the sub-national level, management 
of health services within the district is the responsibility of 
the District Health Management Team (DHMT) headed by 
a District Health Officer (DHO). District health managers 
and service providers participate in policy development 
through representation. They also participate in generation of 
evidence that informs health policy and strategy development 
in addition to using evidence at the local level to improve 
service delivery. At the sub-national level, the DHO and 
a member of the DHMT in charge of supervising health 
facilities within the district were purposively selected and 
interviewed. Within the selected districts, two hospitals 
and two lower level facilities (one public and one PNFP in 
both cases) were purposively selected based on proximity 
to the district headquarters for easy access, and our desire 
to capture the different levels of the healthcare system. The 
medical superintendent or health center employee in-charge 
and one clinical staff member responsible for the outpatients 
department were purposively selected and interviewed at each 
health facility. Detailed information regarding the selected KI 
is shown in Table 1.
Data collection
An interview guide, comprising of open-ended questions 
was developed to explore the views of respondents regarding 
suitable evidence to guide policy development. The interview 
guide was developed by the research team and pre-tested with 
volunteer colleagues in the MoH (n = 2) and the World Health 
Table 1. Key informants
Sector Institution No.




MoH national level 18 11
Managers at the district level 4 9
Service providers 4 7
MoF national level 1 10






Service providers 4 6
Journalists 1 8
CSOs 6 9
Researchers in private 
institutions
2 -
Donors Donors 8 8
Total 51
MoH= Ministry of  Health;  MoF= Ministry of Finance; CSOs= Civil Society 
Organizations.
Organization (WHO) Uganda office (n= 2). The research 
team refined the guide prior to undertaking interviews. 
Respondents were invited by telephone to participate in the 
study and all interviews were conducted face to face by the 
first author. All invited respondents agreed to participate in 
the study.
Data analysis
Interviews were recorded verbatim, transcribed the same day 
and entered into Microsoft Word. Additional notes taken by 
the research team during the interviews were used to enrich 
the transcribed interviews. Interviews lasted on average 30 
minutes. As a first step to formal analysis, the first author read 
through all the interviews and identified emerging issues in 
line with the study objectives. The research team then read all 
interviews to identify emerging issues by type of KI. Inductive 
manifest and latent content analysis techniques (15) were 
undertaken in QSR NVivo 10. Manifest content analysis 
(22) was initially undertaken to assess the visible meaning 
of the text and following which, the underlying meaning was 
explored through latent content analysis (22) an example of 
which is shown in Table 2. 
Converging issues were reviewed by the research team and 
where interpretation differed, consensus was achieved 
through revisiting the raw data. Converging issues were 
grouped under the different themes. The quotations that 
further highlight emerging issues were edited to ensure clarity 
and used where appropriate.
 
Results
Responses regarding what type of evidence was deemed 
suitable for informing policy development were categorized 
under several themes that emerged based on content analysis 
namely: 1) high quality evidence covering different aspects; 
2) local research embedded in local context; 3) routine 
Monitoring and Evaluation (M & E); 4) international 
evidence; 5) clinical trials and systematic reviews; 6) 
observational reports from service providers; 7) community 
reports/cries; and 8) experience, as shown in Table 2. From 
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the quantitative results, the frequency with which different 
types and characteristics of evidence were mentioned by the 
different respondents is shown in Table 3.  
High quality evidence, informing different aspects of 
decision-making was deemed as important given the fact that 
development of successful policies covers several parameters. 
Among the aspects highlighted by the respondents were, 
evidence on cost to assess whether the policy will be 
affordable to the government, community acceptability to 
assess uptake of the policy, cost effectiveness to assess value 
for money, health system capacity to assess implementation 
feasibility and political acceptability. A MoH respondent 
stated that: “When you are trying to change policy, there are 
several things to be considered and we need evidence in all these 
areas for example is it possible to operationalize the policy? Is 
it feasible? Can the country afford? Will the community accept 
the policy?” A private sector respondent further added that: 
“Whatever evidence is there, it should be holistic and should 
capture the social, political, economic and cultural aspects of the 
community and the environment. What are the social aspects 
related to the policy, what are the economic aspects related to 
the policy and what about political aspects. It’s very important 
to consider a holistic approach”. 
Evidence must be of high quality and aspects categorized as 
comprising high quality were a sound methodology, studies 
undertaken in multiple sites showing consistent results and 
the credibility of researchers. A donor respondent remarked 
that: “You need a combination of evidence but must be of high 
quality. If its studies they should be of good methodology, and 
if it is routine data it should be data that is consistent. This 
evidence should not be obtained by chance but the research must 
be carried out in various settings and must be rigorous”. Some 
respondents highlighted the fact that the funding source for 
the research needs to be considered in order to assess the 
objectivity of the research findings. A MoH respondent 
remarked that: “Evidence used in any policy development must 
be credible, and for evidence to be credible, you must look at 
the researchers, the funding source, whether the procedures were 
properly followed and methods are robust”. 
Local evidence was noted to impact more on decision-makers 
given the fact that it relates directly to the context and as such, 
applicable to the situation which you are trying to improve. 
Among the reasons given was the possibility of gathering 
evidence alongside implementation so one can easily know 
what can and cannot work given the fact that research is 
integrated into implementation. A MoH respondent remarked 
that: “The ideal and perfect way would be that famous three 
legged stool for providing service, as you provide services you 
are also teaching and have something to teach with. If you have 
questions you can’t answer you undertaking research. So that 
would be the ideal perfect situation and then you supplement it 
with other people’s evidence and international experience which 
you have to contextualize but; you will be generating your own 
evidence which is responding to your own need”. A private 
sector respondent further added that: “Preference would go 
to local research undertaken within the country because that 
Table 2. Example of the content analysis process
Code Categories Theme
- We need a combination, no one source could be the most used
- We need high quality research on different aspects, clinical, social sciences, costing, 
implementation feasibility, community acceptability
- Evidence on several aspects clinical, costing and supply implications, implementation feasibility
- You need a combination of data but high quality data. If its studies they should be of good 
methodology, appropriate sample size and if it is routine data it should be data that is consistent
- I think every piece of research needs to be considered. The key thing that the policy-maker needs 
to do is to decide which evidence is most appropriate for the local context
Different aspects of 
evidence play different 
roles and all are of 
relevancy to policy 
development




Preference for local research because it depicts the background of the exact factors – social, 
biological – of that locality
- Local studies may have more relevance to Ugandan’s policy-making
- Local-real life research will impact more on decision-makers 
- You need local evidence about which medicines are effective for the local context
- Need for local context data, evidence on costs, implementation feasibility, compliance 
Preference for local 
research done within 
the country because it 
depicts the local context
Local research 
embedded in local 
context
- Routine M & E is useful in monitoring but can also be used for evaluation and definitely provides 
good evidence for policy-making
- Through routine M & E you can assess whether policies are being implemented
M & E data is useful for 
policy-making
Routine M & E data
- International studies need to be considered as well but alongside local data to make sure it fits 
into the context
- Need both real life local research evidence in addition to the international evidence about drug 
efficacy, compliance
International evidence 
used alongside local data
 Contextualized 
international evidence
- Clinical trials, drug efficacy studies especially these ones which compare existing drugs with those 
that have been proposed for adoption
- Systematic review of different papers if various papers published from different settings are all 
speaking about the same thing, this is a good source of information
- Systematic reviews which put together different small studies to get a bigger picture that can give 
you even better more precise information
Decision should be 
based on high quality 
studies carried out in 
different settings, in 
well-controlled settings 
e.g. clinical trials, 
drug efficacy studies, 
systematic reviews
Clinical trials and 
systematic reviews
 M & E= Monitoring and Evaluation.
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research would depict the background of the exact factors - 
social, biological, or political of that locality. International 
research may complement but most important to me is the local 
research done within the country which gives the exact picture 
of that country”. 
Although international evidence plays a role, it must be 
contextualized and triangulated with what locally generated 
evidence has shown. M & E was noted to play a key role in 
some instances for example, monitoring implementation 
of policies and among the noted advantages was the 
ability to provide data on the situation on the ground. A 
parliamentarian remarked that: “People are persuaded by M 
& E because the question they want answered is how are polices 
being implemented and whether we are achieving results”. Some 
respondents however cautioned against the weaknesses in the 
routine M & E systems and emphasized the need to undertake 
research to verify reported achievements and observed 
disease trends. A CSO respondent remarked that: “There are 
times we take decisions based on M & E which is good because 
it gives you trends on how things are happening but sometimes 
to nail that harder, you may need to look at some studies that 
go further to confirm observed trends, but also to highlight the 
weaknesses of our M & E Systems”.
Researchers showed a bias towards clinical trials and 
systematic reviews stating that this is the most credible 
source. A researcher remarked that: “Being a scientist the best 
type of evidence is a well-conducted randomized clinical trial, 
this should be the best evidence on which to base our policies. We 
need several clinical trials and if you get consistent results from 
more than one trial then that is the best evidence scientifically, 
and from my stand point”. 
Community voices are also evidence that can be used in 
policy development as remarked by a journalist in reference 
to policies on health financing: “There was evidence from the 
ground that very many people were not able to afford user fees 
and as a result, they were staying away from the health facilities 
even when they were sick. That was definitely evidence in the 
form of peoples’ testimonies”. 
“Experience” was also identified as a form of evidence that can 
guide policy especially in instances where there is nothing to 
compare with. A researcher stated that: “You may find that in 
some cases, the best evidence is experience. You need somebody 
who has experience in that particular area to guide you; you 
don’t need to commission a study”. 
Different types of polices will require different evidence as 
remarked by a parliamentarian that: “Each policy issue requires 
a certain type of evidence”. The extent of risks associated with 
a given policy has an impact on the nature and scope of 
evidence required. Policies which have wider health system 
implications, call for significantly more resources, affect more 
people and where the risks of success or failure are not very 
clear, are likely to require more evidence on the different 
aspects. A researcher stated that: “If you are going to start a 
social health insurance scheme, the fund requires major policy 
action and you are going to change so many things so you need 
evidence on several aspects. Whilst policies like giving septrin to 
people who are having HIV would not require much evidence 
because septrin is available in the system and people are already 
diagnosed with HIV, all they need is medicine”. 
Discussion
This study has shown that there is neither a single type of 
evidence agreed upon as the most appropriate to inform 
policy development, nor is there any that is deemed best for 
stakeholders in general. Policy development requires several 
types of evidence and the different stakeholders attach more 
importance to different types of evidence. Furthermore, the 
quality of evidence is perceived as a very important attribute 
providing more confidence in the results and enhancing the 
likelihood of KT. 
Our study has highlighted the need for evidence informing 
different aspects of decision-making including political and 
community acceptability, affordability and implementation 
feasibility among others. This mirrors the fact that policy-
makers look for evidence that covers different aspects 
that they are concerned with in the decision-making 
Table 3. Number of respondents for the different categories
























MoH national level 10 8 4 4 2 - 2 2
Mangers at district level - 2 3 - - 2 - -
Service providers 3 4 4 1 - 3  3 -
MoF - 1 1 - 1 - - -
Researchers in public 
universities
1 - - 1 2 - - 1
Parliamentarians 1 - 1 - 1 - - 1
Private 
sector
CSO 2 1 2 1 - - 2 - 
Service providers 1 1 2 - - 1 - -
Journalists 1 1 - - - - 1 -
Researchers in private 
research institutions
- - - 1 1 - - -
Donors 4 2 1 4 2 - 1 -
Total 23 20 18 12 9 6 9 4
M & E= Monitoring and Evaluation; MoH= Ministry of Health; MoF= Ministry of Finance; CSOs= Civil Society Organizations.
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process including factual information, but also context and 
feasibility aspects of a decision. It is not enough that an 
intervention is effective, policy-makers want to know how 
applicable it is and whether it is affordable and acceptable 
by the community. Policies with far reaching consequences 
require more evidence compared to those with minimal 
requirements for implementation and adjustments of current 
practice. Mubyazi and Gonzalez-Block (8) documented a case 
of malaria treatment change in Tanzania where the decision to 
change the first anti-malarial drug given high resistance levels 
was protracted, characterized by the MoH commissioning 
more studies to gather more evidence on different aspects 
of the policy change and implementation including cost, 
implementation feasibility and community acceptability. 
Similarly Basaza et al. (23) documented a case of designing 
a health insurance scheme in Uganda emphasizing the 
need for comprehensive evidence encompassing financial 
feasibility, political acceptability, popular support, impact 
on employment and private sector growth to guide 
decision-making. This emphasizes the need for evidence 
informing different aspects of decision-making and policy 
implementation. 
Scholars have highlighted that different stages of policy 
development may require different types of evidence (24). 
Sutcliffe and Court (24) argue that at the agenda setting stage, 
emphasis is on raising awareness and evidence highlighting 
the magnitude of the problem may play a key role in decision-
making. At the policy formulation stage on, there is need to 
understand the situation and the different options and as such, 
comprehensive evidence linking activity and an outcome, as 
well as the expected cost and impact of an intervention will 
be required. The implementation stage on the other hand 
will require operational evidence, systematic learning and 
evidence from pilots which demonstrate how to implement 
the policy. We however highlight the iterative nature of policy 
development and as such, demarcations in the policy cycle are 
not distinct. For example, Nanyunja et al. (25) documented 
a case of the malaria treatment policy change in Uganda 
where even after a decision had been made on which first 
line antimalarial to adopt, engagement of some actors with 
decision-makers continued and indeed an alternative first 
line treatment was also adopted.
Our study has highlighted the importance of evidence being 
of high quality which is already a documented facilitating 
factor for KT (16,26). The definition of high quality may be 
a matter to be further explored but it is evident that policy-
makers are aware that not all evidence presented to them is 
credible, robust and of value. Evidence needs to win the trust 
of the decision-makers if it is going to be considered for use in 
the policy-making process. 
Different stakeholders lay emphasis on different kinds of 
evidence for varied reasons. For example, while most donors 
preferred comprehensive and international evidence and 
MoH officials looked to comprehensive and local evidence, 
most district health managers preferred local evidence, 
routine M & E reports and observations from service 
providers. Service providers on the other hand preferred 
local evidence and routine M & E whilst researchers preferred 
systematic reviews and clinical trials. Two reasons may 
explain this observation; firstly, expressed preferences may be 
related to the stages of the policy-making process that actors 
are more involved with. Secondly, preferences may be related 
to the level of decision-making they are a part of, that is, sub-
national, national or international.
In the past, researchers have been criticized for their 
preference for, and focus on scientific evidence because of 
its rigor, and this has formed a point of diversion between 
them and policy-makers who are looking for quick solutions 
to address the time bound nature of policy development 
(2). Researchers are however fast recognizing that research 
evidence is just one source of information for policy-
makers (27). Anecdotal evidence however shows that many 
researchers still hold the notion of evidence being in a 
constant hierarchy with non-peer reviewed evidence being 
ranked lower than its peer-reviewed counterpart. However 
our study shows that such ranking may indeed not be a real 
reflection of what different policy-makers deem important at 
any one given decision-making time. 
In a systematic review by Oliver and colleagues (6), the 
researchers pointed out that over a third of the studies they 
included cited policy-makers using evidence other than that 
from peer reviewed research, for example, local data and tacit 
knowledge. In this study, we formed categories of the types 
or forms of evidence respondents deemed important. These 
categories include research in addition to other types evidence 
among which is routine M & E, service provider reports, 
community feedback and experience. These categories fit 
closely with those cited by a systematic review by Orton et 
al. (28) that aimed to synthesize empirical evidence on the 
use of research evidence by public health decision-makers. 
They found that in addition to primary studies and systematic 
reviews, the types of evidence used included, internal 
program evaluations, local and provincial best practices, and 
natural policy experiments among others. In addition the 
categories tally with the five types of evidence influencing 
policy on health inequalities that Whitehead and colleagues 
(29) identified as particularly persuasive with policy-makers. 
These included observational evidence showing the existence 
of a problem; narrative accounts of the impacts of policies 
from the household perspective; controlled evaluations; 
natural policy experiments; and historical evidence. The 
emphasis on research evidence, systematic reviews and 
randomized controlled trials as the ideal evidence in several 
studies in the past may be a reflection of the fact that very 
few studies had explored the views of policy-makers on the 
subject of what evidence is, and their day-to-day use of it in 
policy and decision-making (28). Policy-makers seek robust 
dialogue, critical and creative thinking, and will value tacit 
knowledge like expert opinion alongside research which may 
often be necessary but insufficient for decision-making (27). 
This is a view that is shared by several others including Pang 
(11) who points out that policy-makers for whom access to 
the most relevant and useful evidence is crucial, are constantly 
seeking to answer the questions of whether an intervention 
can work and whether it is worth it. These questions can only 
be answered by evidence from a combination of sources.
In our study, local evidence ranks highly for local policy and 
decision-makers and, evidence from experience is valued too. 
This may highlight the fact that evidence should be applicable 
and acceptable. Several studies involving policy-makers’ 
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views have emphasized this (28) and in fact, Quazi et al. (30) 
advise that researchers must understand that the evidence 
they generate needs to be contextualized for applicability and 
utility. Indeed, it is advised that evidence be interpreted with 
the backdrop of the local context in which the research was 
carried out (31). 
There is an ongoing debate about whether differences exist 
between LIC and High-income Countries (HICs) policy 
processes and their evidence needs. Lavis and colleagues have 
argued against this (32). They believe that the processes are 
generally similar only differing in terms of context, which 
may be due to systems’ issues. On the other hand, some 
scholars believe that these differences are indeed real (33). 
This would explain why LICs’ views regarding what evidence 
is, differs from developed countries’ views. This is perhaps 
enhanced by the uncertainties involved given the weak health 
systems, resource constraints, and population demands faced 
by politicians in LICs which may influence the nature of the 
evidence required. 
Implications for research 
This study highlights the importance of policy-informed 
research agendas. In as much as policy should be informed 
by research, researchers need to be informed by policy in 
order to carry out relevant and context sensitive research, if 
they are going to be of value to the policy-making process. 
Literature highlights that the involvement of policy-makers 
in research is still sub-optimal. For example, Oliver et al’s 
systematic review of 145 studies found 137 study reports were 
written by researchers or people with academic affiliations, 
while policy-makers were credited as authors in only 3 
studies, one of which was a governmental report (6). This 
is a reflection of the suboptimal involvement of users in 
the production process of research. This trend may need to 
change; the involvement of policy-makers makes the research 
a tad nearer their needs and expectations. Furthermore, there 
is a global call for research agendas to be informed by policy. 
It is waste of resources when research is done but not able 
to inform policy or practice, or form a base on which other 
policy relevant research can build. This is especially so in LICs 
where resources are extremely meager and the luxury of doing 
research for the sake of it may not be affordable. Hutchison 
and Carden advise that if researchers want to design and 
implement influential research, they need to understand the 
settings in which the policies they intend to inform are made 
such that, their research strategy aims for the best possible 
effect within that setting (31,34).
In addition, the call for a combination of different types of 
evidence, which implies that research evidence is, but only one 
of several types, calls for researchers to align themselves with 
the policy development process. A lot of non-peer-reviewed 
research is commissioned by government departments to 
inform decisions and policies while a lot of the peer-reviewed 
research is frequently done uninformed by the policy 
process, thereby being released at a time it is not of interest 
no matter how fascinating the results are. In such instances, 
the non-peer-reviewed research would have higher chances 
of informing the policy and decision-making processes as 
compared to peer-reviewed scholarly research. Researchers 
need to endeavor to inform themselves of the stages of policy 
development, and combine this with knowledge on the 
priorities of the policy agenda as they design their research.
Despite being close to the problems and situations, and 
the context in general, research capacity in LICs is low 
in all aspects (35). Some of this weakness is owed to a 
limited number of skilled persons to carry out research, a 
lack of research infrastructure, overdependence on donor 
funding for research activities, uncoordinated initiatives, 
inadequate political will, the transfer of data from Low- and 
Middle-Income Countries (LMICs) to developed countries, 
publication research without any feedback to policy-makers 
in the source countries, and a focus on research that offers 
huge financial returns on investment, instead of topics that 
are more locally relevant (36). Considering the preference for 
local evidence, this means there is a call for more research to 
be carried out locally. The inter academy medical panel notes 
that national and regional science and medical academies are 
better placed than foreign institutions to influence policy-
makers with evidence, and to support research capacity 
building in countries and regions where they operate (37). 
Given the weak research capacity in LICs, innovative ways 
to meet this need are demanded. North to South cooperation 
is inevitable but so is South to South collaboration, to avoid 
duplication of activities and have more coordinated initiatives, 
and furthermore share resources like equipment at given 
centers of excellence. 
Implications for policy
The findings of this study highlight some implications for 
policy-makers and stakeholders. In order to ensure that 
policy-makers receive evidence that meets their expectations, 
information on their needs is necessary. This could be in the 
form of national research agendas and or, needs assessment 
findings. Such an initiative would need to be routine and 
the needs updated regularly involving a dialogue between 
research producers and policy-makers as research users. 
Policy-makers have expressed a leaning towards non-peer- 
reviewed evidence, the lack of skills to make optimal use of 
research evidence may explain this observation. This would 
represent a missed opportunity for research evidence to 
inform the policy-making process. It would at the same time 
highlight the role of knowledge brokers or KT platforms 
which are national or regional level institutions committed 
to fostering linkages and exchange across health systems, 
skillfully acting as intermediaries between research and 
policy (38–40).
Strengths and weaknesses of the study
Our study has several strengths; firstly, we interviewed a 
wide and diverse group of stakeholders allowing for a broad 
picture on the subject. Secondly, the diverse nature of the 
respondents provides a rich multi disciplinary and multi 
institutional perspective on evidence deemed appropriate to 
inform policy decisions. 
Our study has limitations as well among which is the social 
desirability bias where respondents report what they think the 
researcher would like to hear and give responses displaying 
‘acceptable’ attitudes and behaviors. However this may not 
have been a big problem as we did not go out to explore how 
much or what they were doing. Some scholars have noted that 
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different types of evidence are needed at the different stages 
of policy development but our study did not explore this 
aspect. We however feel that this limitation does not affect the 
relevance of our results given the fact that policy development 
is iterative and in majority of cases one cannot draw clear 
demarcations between the different stages. 
Conclusion
What LICs like Uganda categorize as evidence suitable for 
informing health policy development encompasses several 
types and no one source is deemed superior to others. 
Evidence needs to be holistic, of high quality, applicable 
and acceptable to the users. Preference for locally generated 
evidence has been expressed but the quality of which needs 
be enhanced. In as much as policy needs to be informed by 
research, researchers also need to be informed by policy in 
order to carry out relevant and context sensitive research. 
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